Subclinical Aldosteronism & Increased MACE Risk
Subclinical Aldosteronism May Drive Hypertension and Cardiovascular Risk in Normotensive Individuals
Table of Contents
New research suggests that a significant portion of individuals wiht normal blood pressure may harbor subclinical primary aldosteronism (PA), a condition that could predispose them to future hypertension and major adverse cardiovascular events (MACE). Teh findings challenge traditional approaches to hypertension management and advocate for a more personalized, mechanism-based strategy.
A recent study has shed light on the potential underdiagnosis of primary aldosteronism (PA), a condition characterized by the overproduction of aldosterone, a hormone that regulates blood pressure and electrolyte balance. While PA is a known cause of secondary hypertension,this new research indicates that its subclinical form – where aldosterone levels are elevated but blood pressure may still be within the normal range – could be a significant,yet frequently enough overlooked,contributor to cardiovascular disease risk.
The study, which followed participants for a median of 10.8 years, found that 2.8% of individuals developed a MACE, including myocardial infarction, stroke, and hospitalization for heart failure. Notably, the researchers identified specific hormonal markers associated with an increased risk of these adverse events.
Key Findings: renin and aldosterone-Renin Ratio as Predictors
The research highlighted a strong correlation between lower renin concentrations and a higher aldosterone-to-renin ratio (ARR) with an increased risk of MACE.
Lower Renin Concentration: Participants with lower renin levels exhibited a considerably higher risk of MACE. The study reported an adjusted hazard ratio (aHR) of 2.22 (95% CI, 1.02-4.76) for lower renin. Higher Aldosterone-Renin Ratio (ARR): Conversely, a higher ARR was also a strong predictor of MACE, with an aHR of 2.43 (95% CI, 1.15-5.12).
Importantly, these associations remained significant even after adjusting for blood pressure, suggesting that these hormonal imbalances can drive cardiovascular risk independently of overt hypertension.
Defining High-Risk Thresholds
The study further refined these findings by identifying specific thresholds for renin and ARR that indicate a heightened risk:
Renin concentration of 4 ng/L or Lower: Individuals with renin levels at or below this threshold were found to have a 2.1-fold higher risk for MACE (95% CI, 1.21-3.72).
ARR of 70 pmol/L per ng/L or More: Those with an ARR of 70 pmol/L per ng/L or higher faced a twofold increased risk for MACE (aHR, 2.03; 95% CI, 1.09-3.80).
The Combined Impact: A Synergistic Risk
The most striking observation was the compounded risk faced by individuals who met both criteria. Approximately 21% of the study population fell into this high-risk category,demonstrating a 2.4 times greater likelihood of experiencing a MACE (aHR, 2.42; 95% CI, 1.25-6.48). The researchers noted that a significant majority (over 80%) of participants with a high ARR also had low renin levels, underscoring the interconnectedness of these hormonal markers.
Shifting Paradigms in Hypertension Management
The study’s implications extend beyond identifying at-risk individuals. They call for a fundamental shift in how hypertension and cardiovascular risk are assessed and managed.
The Prevalence of Subclinical PA in Normotensive Individuals
A key takeaway from the research is the potential for subclinical PA to be prevalent even in individuals with normal blood pressure. Dr. Hundemer, a lead researcher, suggested that many cases of hypertension initially labeled as “primary” or “essential” might actually be aldosterone-mediated due to underlying subclinical PA. This highlights a critical gap in current diagnostic and screening protocols.
Towards Personalized Cardiovascular Care
The findings strongly advocate for a move away from a “one-size-fits-all” approach to hypertension management. Rather, a more personalized strategy that targets the specific underlying mechanisms driving hypertension and cardiovascular disease in each individual is needed. This could involve earlier and broader screening for conditions like subclinical PA, even in those with seemingly normal blood pressure.